Dendritic cell vaccine - Bioclones/Hemispherx Biopharma

Drug Profile

Dendritic cell vaccine - Bioclones/Hemispherx Biopharma

Alternative Names: Cancer vaccine - Bioclones; Patient-specific DC immunotherapy vaccine - Bioclones/Hemispherx Biopharma

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioclones
  • Developer Bioclones; Hemispherx Biopharma
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Prostate cancer
  • No development reported Cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in South Africa (Parenteral, Injection)
  • 14 Jul 2014 Bioclones and Hemispherx agree to collaborate in development of an adjuvanted form of the dendritic cell vaccine
  • 14 Jul 2014 Preclinical trials in Breast cancer in South Africa (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top